Press-release for stocks related to biotech-bay for lly

tags : Biotech-bay symbols : Lly

save search

Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 25.87% | O: 0.07% H: 0.0% C: 0.0%
series

Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published: 2023-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 28.4% | O: -0.84% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -8.74% | O: 0.77% H: 0.0% C: 0.0%
thn391 treatment dementia trial potential results

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 37.84% | O: -1.77% H: 0.0% C: 0.0%
NKTR | News | $1.38 -2.82% -2.16% 960K

Health Technology

| 131.7% | O: -2.01% H: 4.52% C: -2.35%
t-cell congress therapeutics therapy

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
Published: 2023-04-27 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 99.91% | O: 3.98% H: 1.86% C: -0.23%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -17.89% | O: -3.56% H: 0.0% C: 0.0%
neurodegenerative

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 121.84% | O: 0.86% H: 0.42% C: -1.26%
ARE | News 4 | $119.65 0.13% 0.29% 680K

Finance

| -28.69% | O: -1.29% H: 1.54% C: 0.98%
antibody peanut program

Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0

Health Technology

| -4.86% | O: -0.35% H: 0.0% C: -2.69%
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 109.58% | O: 0.3% H: 1.86% C: 0.82%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -0.62% | O: 0.02% H: 0.0% C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M

Health Technology

| -35.45% | O: 1.05% H: 0.2% C: -0.16%
treatment designation medical granted review china

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 146.94% | O: -1.18% H: 1.46% C: 0.05%
ALXO M | $16.22 4.65% 4.56% 260

Commercial Services

| 26.82% | O: 2.97% H: 6.15% C: -1.44%
trial cancer phase 2

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 132.44% | O: 0.99% H: 0.0% C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M

Health Technology

| -33.12% | O: -0.08% H: 0.0% C: 0.0%
ibi362 communications chinese diabetes results phase 2b

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
SANA | $8.58 6.06% 5.71% 1.2M

| 61.13% | O: -6.1% H: 9.2% C: 8.6%
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 140.45% | O: -0.9% H: 0.0% C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M

Health Technology

| -30.99% | O: -0.4% H: 0.25% C: -0.07%
treatment drug application

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
Published: 2022-04-26 (Crawled : 13:20) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 163.75% | O: 0.34% H: 1.41% C: -1.17%
RIGL | $1.125 -1.32% -1.33% 6.5M

Health Technology

| -57.36% | O: -0.38% H: 4.92% C: -4.55%
conference report results

Innovent Announced 2021 Annual Results
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 157.91% | O: 0.13% H: 0.38% C: -1.25%
results

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 204.01% | O: -1.97% H: 0.5% C: -0.88%
pemazyre treatment ema ces approval

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Published: 2022-01-10 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 189.49% | O: -0.5% H: 0.0% C: 0.0%
ALXO M | $16.22 4.65% 4.56% 260

Commercial Services

| -16.82% | O: -0.46% H: 2.63% C: 1.7%
milestone

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
INCY | $51.74 0.17% 0.14% 1.6M

Health Technology

| Email alert Add to watchlist
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| Email alert Add to watchlist
tyvyt new drug application drug china

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 210.02% | O: 1.27% H: 0.0% C: 0.0%
NKTR | News | $1.38 -2.82% -2.16% 960K

Health Technology

| -89.05% | O: -3.33% H: 0.0% C: 0.0%
nktr-255 ema car-t therapeutics therapy

Rigel Pharmaceuticals Provides Update on COVID-19 Program
Published: 2021-08-13 (Crawled : 12:15) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 185.5% | O: 0.2% H: 0.0% C: 0.0%
RIGL | $1.125 -1.32% -1.33% 6.5M

Health Technology

| -72.64% | O: -16.22% H: 0.0% C: 0.0%
covid covid-19 program

Amgen Reports Second Quarter 2021 Financial Results
Published: 2021-08-03 (Crawled : 23:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 205.03% | O: -0.75% H: 5.97% C: 4.59%
XNCR | $19.02 3.54% 3.57% 760K

Health Technology

| -38.39% | O: 0.55% H: 1.32% C: 1.03%
REGN | News | $906.54 -0.09% -0.08% 280K

Health Technology

| 57.08% | O: -0.05% H: 1.86% C: 1.67%
BGNE | $144.12 3.69% 3.48% 150

Health Technology

| -55.98% | O: 0.21% H: 4.53% C: 4.06%
AMGN | News | $273.01 -0.19% -0.17% 400

Health Technology

| 13.85% | O: 0.4% H: 1.51% C: 1.38%
financial results results report

Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology